Is My Patient’s Prostate Cancer Aggressive?

Prolaris, the first prognostic test that offers a look inside the molecular biology of prostate cancer, is finding the wolf in sheep’s clothing

Prolaris®

Prolaris was developed to better measure disease aggressiveness by measuring the expression level of genes involved with cell proliferation. Prolaris adds critical information about prostate cancer, and, in conjunction with clinical parameters such as Gleason score and PSA, helps the physician and patient make personalized treatment decisions for prostate cancer.

Learn More About Prolaris Testing

The National Comprehensive Cancer Network (NCCN)

Released guidelines that recommend hereditary cancer testing for patients that meet the following criteria:1

Red Flags for Hereditary Cancer related to your Prostate Cancer patient:

  • Prostate cancer patient with a Gleason Score of 7+

  • AND they have one or more family members with any of the following:

    • Breast Cancer ≤ 50 years old

    • Ovarian Cancer

    • Pancreatic Cancer

    • Prostate Cancer with Gleason Score of 7+

Knowing a patient’s genetic status could also help prevent cancer in family members.

Increased screening starting at earlier ages is recommended. Additionally, some patients may choose to have preventive surgeries to drastically reduce the risk of developing certain cancers.

Cancer risks for patients with a hereditary cancer syndrome:2

FOR MEN:

Breast Cancer Risk up to 68x the general population.

Prostate Cancer Risk up to 1.5x the general population.

Pancreatic Cancer Risk up to 7x the general population.

Increased risk for Melanoma and Colon Cancer.

FOR WOMEN:

Breast Cancer Risk up to 11x the general population.

Ovarian Cancer Risk up to 44x the general population.

Uterine Cancer Risk up to 47x the general population.

Increased risk for Melanoma, Pancreatic Cancer and Colon Cancer.

Myriad myRisk™ Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing.

Prostate cancer patients with BRCA mutations are associated with poor survival outcomes and should be considered for tailored clinical management.3

  • Poly (ADP-ribose) polymerase (PARP) inhibitors have specific activity in BRCA-associated cancers, including prostate cancer.4
  • Mutation carriers may also respond better to platinum-based chemotherapy.4
  • Screening for secondary cancers should be included in management.

Download A Free Risk Assessment Sheet

Evaluate patients with prostate cancer who may be candidates for hereditary cancer testing. This risk assessment questionnaire can be used to help identify patients with a family history of cancer who may be appropriate for testing.

Order Prolaris®, myRisk™, and other tests

Waiting for results can increase patient anxiety and delay your medical decisions. Myriad believes optimal patient care should include a rapid turnaround-time for test results. Myriad myRisk provides an average turnaround-time of 2-3 weeks.

  1. NCCN Clinical Practice Guidelines in Oncology Version 2.2015
  2. For reference and supporting data on the information provided visit www.MyriadPro.com/References
  3. Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013 May 10;31(14):1748-57
  4. Bratt O, et al. Clinical Management of Prostate Cancer in Men with BRCA Mutations. Eur Urol. 2015 Aug;68(2):194-5